ES2086669T3 - Derivados hidrosolubles de taxol con actividad anti-neoplasica. - Google Patents

Derivados hidrosolubles de taxol con actividad anti-neoplasica.

Info

Publication number
ES2086669T3
ES2086669T3 ES92308421T ES92308421T ES2086669T3 ES 2086669 T3 ES2086669 T3 ES 2086669T3 ES 92308421 T ES92308421 T ES 92308421T ES 92308421 T ES92308421 T ES 92308421T ES 2086669 T3 ES2086669 T3 ES 2086669T3
Authority
ES
Spain
Prior art keywords
taxol
cyz
oxi
synthesized
sodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92308421T
Other languages
English (en)
Spanish (es)
Inventor
David G I Kingston
Zhi-Yang Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Tech Intellectual Properties Inc
Original Assignee
Virginia Tech Intellectual Properties Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intellectual Properties Inc filed Critical Virginia Tech Intellectual Properties Inc
Application granted granted Critical
Publication of ES2086669T3 publication Critical patent/ES2086669T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES92308421T 1991-10-15 1992-09-16 Derivados hidrosolubles de taxol con actividad anti-neoplasica. Expired - Lifetime ES2086669T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/774,107 US5278324A (en) 1990-08-28 1991-10-15 Water soluble derivatives of taxol

Publications (1)

Publication Number Publication Date
ES2086669T3 true ES2086669T3 (es) 1996-07-01

Family

ID=25100263

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92308421T Expired - Lifetime ES2086669T3 (es) 1991-10-15 1992-09-16 Derivados hidrosolubles de taxol con actividad anti-neoplasica.

Country Status (13)

Country Link
US (1) US5278324A (de)
EP (1) EP0537905B1 (de)
KR (1) KR930007925A (de)
AT (1) ATE135002T1 (de)
CA (1) CA2080393A1 (de)
CZ (1) CZ312292A3 (de)
DE (1) DE69208802T2 (de)
DK (1) DK0537905T3 (de)
ES (1) ES2086669T3 (de)
FI (1) FI924678L (de)
GR (1) GR3020109T3 (de)
NZ (1) NZ244754A (de)
PL (2) PL299303A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5973160A (en) 1992-12-23 1999-10-26 Poss; Michael A. Methods for the preparation of novel sidechain-bearing taxanes
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
TW467896B (en) 1993-03-19 2001-12-11 Bristol Myers Squibb Co Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6005120A (en) 1993-07-20 1999-12-21 Florida State University Tricyclic and tetracyclic taxanes
AU8052194A (en) * 1993-10-20 1995-05-08 Enzon, Inc. 2'- and/or 7- substituted taxoids
DE69527346T2 (de) * 1994-01-11 2003-02-13 The Scripps Research Institute, La Jolla Sich selbst bildende taxo-diterpenoid nanostrukturen
GB9405400D0 (en) * 1994-03-18 1994-05-04 Erba Carlo Spa Taxane derivatives
US5801191A (en) * 1995-06-01 1998-09-01 Biophysica Foundation Taxoids
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
ATE309235T1 (de) * 1995-09-12 2005-11-15 Zeneus Pharma Ltd Hydrolyse-einleitende hydrophobe taxane derivate
US6051600A (en) * 1995-09-12 2000-04-18 Mayhew; Eric Liposomal hydrolysis-promoting hydrophobic taxane derivatives
EP1229030B1 (de) * 1995-09-12 2005-11-09 Zeneus Pharma Limited Hydrolyse-einleitende hydrophobe Taxane Derivate
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US5854278A (en) * 1995-12-13 1998-12-29 Xechem International, Inc. Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents
US5807888A (en) * 1995-12-13 1998-09-15 Xechem International, Inc. Preparation of brominated paclitaxel analogues and their use as effective antitumor agents
US6177456B1 (en) 1995-10-02 2001-01-23 Xechem International, Inc. Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor
US5840748A (en) * 1995-10-02 1998-11-24 Xechem International, Inc. Dihalocephalomannine and methods of use therefor
US5654448A (en) * 1995-10-02 1997-08-05 Xechem International, Inc. Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE69734060T2 (de) 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
GB9705903D0 (en) 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
CZ2003837A3 (cs) * 2000-09-22 2004-12-15 Bristol-Myers Squibb Company Způsob pro snížení toxicity při kombinovaných chemoterapiích
CA2440935A1 (en) 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP1427407A4 (de) 2001-03-23 2005-05-11 Luitpold Pharm Inc Fettamin-arzneimittel-konjugate
DE60220519T2 (de) * 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
PL368945A1 (en) 2001-11-30 2005-04-04 Bristol-Myers Squibb Company Paclitaxel solvates
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
AU2003225495B2 (en) * 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
US20040254419A1 (en) * 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
US20070010702A1 (en) * 2003-04-08 2007-01-11 Xingwu Wang Medical device with low magnetic susceptibility
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
WO2005061710A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
WO2006050732A2 (en) * 2004-11-09 2006-05-18 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
MX2007005558A (es) * 2004-11-09 2008-01-31 Santaris Pharma As Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a.
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
EP1832577A1 (de) * 2006-03-07 2007-09-12 Sanofi-Aventis Verbesserte Pro-Pharmaka von CC-1065-Analoga
EP2029156A4 (de) * 2006-05-01 2010-07-21 Univ Southern California Kombinationstherapie zur krebsbehandlung
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
WO2009090614A2 (en) * 2008-01-16 2009-07-23 Anwar Rayan Derivatives of taxol and closely related compounds
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
US8642063B2 (en) * 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol

Also Published As

Publication number Publication date
US5278324A (en) 1994-01-11
DK0537905T3 (da) 1996-07-22
FI924678A0 (fi) 1992-10-15
PL299303A1 (en) 1994-01-10
FI924678A7 (fi) 1993-04-16
DE69208802D1 (de) 1996-04-11
ATE135002T1 (de) 1996-03-15
CZ312292A3 (en) 1993-05-12
GR3020109T3 (en) 1996-08-31
EP0537905B1 (de) 1996-03-06
KR930007925A (ko) 1993-05-20
DE69208802T2 (de) 1996-10-02
FI924678L (fi) 1993-04-16
PL296256A1 (en) 1993-10-18
NZ244754A (en) 1995-03-28
EP0537905A1 (de) 1993-04-21
CA2080393A1 (en) 1993-04-16

Similar Documents

Publication Publication Date Title
ES2086669T3 (es) Derivados hidrosolubles de taxol con actividad anti-neoplasica.
RU98107259A (ru) Новые производные пиридонкарбоновой кислоты или их соли и антибактериальные средства, содержащие такие соединения в качестве активных компонентов
CA2232728A1 (en) Novel pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components
IL194483A0 (en) Methods for making proteins containing free cysteine residues
BE873844A (fr) Derives d'acides aryloxy-propioniques optiquement actifs, utilisables comme herbicides
ATE103273T1 (de) Carbonsaeure- und sulfonsaeureamide.
ATE105285T1 (de) Salicylaldehyd- und salicylsaeurederivate sowie deren schwefelanaloge, verfahren zu ihrer herstellung und ihre verwendung als herbizide und bioregulatoren.
EA199900935A1 (ru) Соединения индазоламида в качестве серотонинергических агентов
RU93056600A (ru) Фенокси- и феноксиалкилпиперидиновые соединения и антивирусная композиция
DE69318238D1 (de) Benzopyran-Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Zellenschutzmittel
DE69108739D1 (de) Phosphonsäurederivate als entzündungshemmende mittel.
ES8505518A1 (es) Procedimiento para preparar derivados de aminoacidos
ES2063050T3 (es) Derivados de alcoxi-2-oxo-1,2-dihidroquinoxalina substituida en posicion 6.
IT1089632B (it) Sali coloranti di elevata solubilita' in solventi organici
CA2199568A1 (en) Multifunctional vinyl cyclopropane derivatives
DE69825977D1 (de) Antivirale mittel
KR830004217A (ko) 약학적 활성이 있는 펩타이드
BG96487A (bg) Р-заместени производни на 4-оксибутанамина,методи за получаването им и тяхното приложение
GB9305163D0 (en) Chemical compositions
RU94016524A (ru) Циклические уретаны, пригодные в качестве средств против аритмии и фибриляции, способ лечения, фармацевтическая композиция
DE69506272D1 (de) Bestimmung von freien radikalen
GR900100356A (el) Νέα παράγωγα 9α-υδροξυ-3-οξο4,24(25)-στιγμασταδιέν-26-οϊκού οξέος και μέ?οδος για την παρασκευή τους.
JPS52122358A (en) Novel methano-anthracene derivatives
MX9205989A (es) Derivados de hidroquinona sustituida
EP0697291A4 (de) 4-hydroxy-4'-isopropoxydiphenylsulfon-entwicklerzusammensetzungen, nasspulverisierungsverfahren und dispersion

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 537905

Country of ref document: ES